Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Recruiting · NCT06720766 · Observational (researchers observe without assigning treatment) · Lead sponsor: The Third People's Hospital of Chengdu
View the official record on ClinicalTrials.gov →Interventions studied
FibbroScan and biopsy
What this trial is about
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients aged 18 years or older who provided written informed consent
- Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD
- Patients who schedule to undergo FibroScan examination
Exclusion criteria
- Patients with ascites or pregnant women
- Patients with any active implantable medical device (such as a pacemaker or defibrillator)
- Patients who have undergone liver transplantation
- Patients with cardiac failure and/or significant valvular disease
- Patients with haemochromatosis
- Patients who have refused to undergo LB or blood tests
- Patients with a confirmed diagnosis of active malignancy, or other terminal disease
- Patients participating in another clinical trial within the preceding 30 days
Where it is running
1 location listed.
- The Third People's Hospital of Chengdu - Chengdu, Sichuan, China